Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Curr Opin Immunol. 2020 Aug;65:14-20. doi: 10.1016/j.coi.2020.01.008. Epub 2020 Mar 31.
Messenger RNA (mRNA) vaccines represent a relatively new vaccine class showing great promise for the future. This optimism is built on recently published studies demonstrating the efficacy of mRNA vaccines in combatting several types of cancer and infectious pathogens where conventional vaccine platforms may fail to induce protective immune responses. These results would not have been possible without critical recent innovations in the field, such as the development of safe and efficient materials for in vivo mRNA delivery and advanced protocols for the production of high quality mRNA. This review summarizes the most important developments in mRNA vaccines from the past few years and discusses the challenges and future directions for the field.
信使 RNA(mRNA)疫苗代表了一类相对较新的疫苗,具有广阔的未来前景。这种乐观情绪建立在最近发表的研究基础上,这些研究表明 mRNA 疫苗在对抗几种类型的癌症和传染病原方面具有疗效,而传统的疫苗平台可能无法诱导保护性免疫反应。如果没有该领域最近的关键创新,这些结果是不可能实现的,例如用于体内 mRNA 传递的安全高效材料的开发以及高质量 mRNA 生产的先进方案。本文综述了过去几年中 mRNA 疫苗的最重要进展,并讨论了该领域的挑战和未来方向。